Calculate total daily morphine milligram equivalents (MME) from multiple opioids with CDC reference bands, equianalgesic conversion context, and naloxone review cues.
Morphine milligram equivalents (MME) provide a common scale for comparing opioid exposure across different medications. The CDC 2022 Clinical Practice Guideline for Prescribing Opioids uses daily MME bands as caution points for risk review, especially once the total reaches or exceeds 50 MME/day. Higher daily MME is associated with progressively higher overdose risk in observational studies, but the number is still only one part of the full clinical picture.
This calculator converts up to three concurrent opioids to total daily MME using widely cited equianalgesic conversion factors from CDC, CMS, and clinical pharmacology references. It shows the contribution of each medication, adds overdose-risk context, highlights benzodiazepine co-use, and flags ranges where naloxone access is commonly reviewed.
Equianalgesic conversions remain approximations with substantial inter-patient variability. Methadone conversions are especially complex because the ratio changes with dose, the half-life is long and variable, and QTc risk can matter. When clinicians compare opioid rotation scenarios, many references apply a 25-50% reduction for incomplete cross-tolerance rather than treating the raw MME output as a direct new-dose instruction.
MME calculation helps compare opioid regimens on a common scale so total daily exposure is easier to review. This calculator combines multiple opioids, shows the contribution of each medication, and highlights dose ranges that deserve closer clinical review.
Total daily MME = Σ (daily dose × conversion factor) for each opioid. Conversion factors: morphine oral = 1.0, oxycodone = 1.5, hydromorphone oral = 4.0, fentanyl patch (mcg/hr) × 2.4, codeine = 0.15, tramadol = 0.1.
Result: 90 MME/day — Very high review band. Naloxone access is commonly reviewed at this range.
Oxycodone 10 mg × 4 = 40 mg/day × 1.5 = 60 MME. Morphine 15 mg × 2 = 30 mg/day × 1.0 = 30 MME. Total = 90 MME/day, which places the regimen in a very high review band under the CDC 2022 caution thresholds.
The 2022 CDC Clinical Practice Guideline replaced the controversial 2016 version, which was sometimes misapplied as inflexible dose limits leading to patient harm through forced tapers. The 2022 guideline emphasizes individualized assessment, shared decision-making, and avoidance of abrupt discontinuation. Key recommendations: use the lowest effective dose, avoid increasing to ≥ 50 MME/day without reassessment, consider offering naloxone at ≥ 50 MME/day, and use PDMP data to identify concurrent prescriptions. The guideline explicitly states that specific numeric thresholds should not be applied as rigid ceilings — clinical judgment remains paramount.
In 2022, over 80,000 Americans died from opioid-involved overdose deaths. While the current crisis is driven primarily by illicitly manufactured fentanyl, prescription opioid misuse remains a significant contributor, and most people with opioid use disorder initially encountered opioids through prescriptions. MME review, PDMP review, naloxone-access discussions, and multimodal pain management are all part of the broader safety context that sits around prescription opioids.
Opioid rotation (switching from one opioid to another) is one setting where MME tables are often used, especially when the current regimen is not fitting well. A common comparison workflow is to total the current daily MME, translate it through equianalgesic ratios, then apply a cross-tolerance reduction rather than treating the raw conversion as a direct new-dose instruction. That is why this page works best as a review worksheet, not as a rotation order set.
Last updated:
This page multiplies each opioid's total daily dose by a published oral morphine conversion factor, then sums those values into a worksheet total daily MME. It keeps the contribution of each medication visible so concurrent opioid products can be reviewed together, and it places the total beside CDC caution bands and naloxone-review context.
The result is a comparison tool, not a direct opioid-rotation order. Conversion factors are approximations, methadone and transdermal fentanyl require extra caution, and any real dose change still depends on clinical response, incomplete cross-tolerance, co-medications, and the broader pain-management plan.
An MME is a conversion factor that expresses the dose of any opioid as the equivalent dose of oral morphine. For example, 10 mg of oral oxycodone has a conversion factor of 1.5, so it equals 15 MME. This standardization allows comparison of total opioid burden across different medications. The CDC uses MME thresholds to guide prescribing risk assessment.
Epidemiologic studies show that patients on ≥ 90 MME/day have substantially higher overdose risk than patients on < 20 MME/day. CDC 2022 treats ≥50 and ≥90 MME/day as caution points for closer reassessment, not as rigid dose ceilings. Some patients with cancer pain, palliative needs, or unusual opioid histories may still sit above those bands, which is why the total works best as review context rather than as a stand-alone rule.
Methadone has unique pharmacology: incomplete cross-tolerance with other mu-opioid agonists, NMDA receptor antagonism, dose-dependent conversion ratios (the ratio increases dramatically at higher doses), extremely long and variable half-life (8-59 hours), and risk of QTc prolongation and torsades de pointes. A patient on morphine 60 mg/day converts to methadone at a 4:1 ratio, but a patient on morphine 300 mg/day converts at 12:1. Methadone rotations should only be performed by experienced clinicians with careful monitoring.
CDC 2022 highlights naloxone access for patients on ≥50 MME/day, concurrent benzodiazepines, history of overdose or substance use disorder, or other factors that increase overdose risk. This page therefore uses naloxone as review context, not as a substitute for clinician judgment about whether a specific patient should have naloxone on hand.
No. Equianalgesic ratios are based on limited studies and have significant inter-patient variability (often 2-5 fold). Factors affecting individual response include genetics, organ function, age, concurrent medications, and tolerance. When clinicians compare a possible opioid rotation, many references reduce the raw equianalgesic total by 25-50% instead of treating the calculator output as a direct replacement dose.
The CDC 2022 Clinical Practice Guideline is intended for outpatient clinicians prescribing opioids for chronic pain in adults, excluding pain management related to sickle cell disease, cancer-related pain treatment, palliative care, and end-of-life care. Patients with cancer pain or those receiving palliative/hospice care may appropriately need higher opioid doses without the same threshold-based restrictions.